204 related articles for article (PubMed ID: 31388368)
1. The Challenges of Pediatric Drug Development.
Rose K
Curr Ther Res Clin Exp; 2019; 90():128-134. PubMed ID: 31388368
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. The Meanings of "Pediatric Drug Development".
Rose K; Grant-Kels JM
Ther Innov Regul Sci; 2019 Nov; 53(6):767-774. PubMed ID: 30526039
[TBL] [Abstract][Full Text] [Related]
4. Pediatric Melanoma and Drug Development.
Rose K; Grant-Kels JM
Children (Basel); 2018 Mar; 5(3):. PubMed ID: 29558389
[TBL] [Abstract][Full Text] [Related]
5. Questionable Industry-Sponsored Postneonatal Pediatric Studies in Slovenia.
Rose K; Neubauer D; Grant-Kels JM
Curr Ther Res Clin Exp; 2019; 90():86-91. PubMed ID: 31388360
[TBL] [Abstract][Full Text] [Related]
6. Too Many Avoidable Suicides Occur Worldwide in Young Patients.
Rose K; Neubauer D; Grant-Kels JM
Rambam Maimonides Med J; 2019 Oct; 10(4):. PubMed ID: 31545703
[TBL] [Abstract][Full Text] [Related]
7. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
Rose K
Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
[TBL] [Abstract][Full Text] [Related]
8. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
9. Children with multiple sclerosis should not become therapeutic hostages.
Rose K; Müller T
Ther Adv Neurol Disord; 2016 Sep; 9(5):389-95. PubMed ID: 27582894
[TBL] [Abstract][Full Text] [Related]
10. Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare?
Rose K; Walson PD
Paediatr Drugs; 2017 Dec; 19(6):515-522. PubMed ID: 28889403
[TBL] [Abstract][Full Text] [Related]
11. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
12. Rational Use of Medicine in Children-The Conflict of Interests Story. A Review.
Rose K; Neubauer D; Grant-Kels JM
Rambam Maimonides Med J; 2019 Jul; 10(3):. PubMed ID: 31335307
[TBL] [Abstract][Full Text] [Related]
13. Mandatory requirements for pediatric drug development in the EU and the US for novel drugs-A comparative study.
Christiansen H; De Bruin ML; Hallgreen CE
Front Med (Lausanne); 2022; 9():1009432. PubMed ID: 36388912
[TBL] [Abstract][Full Text] [Related]
14. Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients?
Rose K; Walson PD
Clin Ther; 2017 Feb; 39(2):253-265. PubMed ID: 28159363
[TBL] [Abstract][Full Text] [Related]
15. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
16. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
17. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
18. Neurology's vital role in preventing unnecessary and potentially harmful pediatric studies.
Rose K; Ettienne EB; Grant-Kels JM; Striano P; Neubauer D; Tanjinatus O
Expert Rev Neurother; 2022 Mar; 22(3):209-219. PubMed ID: 35213279
[TBL] [Abstract][Full Text] [Related]
19. Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health.
Rose K; Kopp MV
Pediatr Allergy Immunol; 2015 Dec; 26(8):695-701. PubMed ID: 26495999
[TBL] [Abstract][Full Text] [Related]
20. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.
Boesen K; Gøtzsche PC; Ioannidis JPA
Epidemiol Psychiatr Sci; 2021 Apr; 30():e35. PubMed ID: 33926608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
